News

The company will evaluate around 20 patients with type 1 diabetes in the Phase IIa trial. The results from a Phase I trial demonstrated that the action of

CNX-011-67, a potent and selective GPR40 agonist, is a small molecule candidate that acts on the pancreatic beta cells and enhances glucose sensitivity, insulin secretion and reduce metabolic

The company expects to roll out AccuDial Children’s pain and fever medications with acetaminophen in five flavors: cherry, dye-free cherry, bubblegum, strawberry, and grape in the US. BroadMed

Remoxy, which is based on Durect’s Oradur technology, is an experimental drug that is a controlled release formulation of oxycodone for moderate-to-severe chronic pain designed to reduce potential

BioThrax is indicated to prevent anthrax infection and is also indicated for the active immunization of adults who are at high risk of exposure to anthrax. BioThrax is

The pRED French R&D Institute will be managed by a Roche academic team which will be in charge of building new research networks with French academic partners, leveraging

InVasc’s INV-144 is a combination drug of losartan and alpha Lipoic Acid (ALA), which is used to slow down the progression of chronic kidney disease (CKD) in patients

Following the acquisition, the plant will be licensed to produce N-acetylgalactosamine 6-sulfatase (GALNS) by 2015. BioMarin CEO Jean-Jacques Bienaime said they believe that additional manufacturing capabilities beyond their

Glybera is used to treat patients with the genetic disorder lipoprotein lipase deficiency (LPLD). AMT CEO Jorn Aldag said they believe that there is an indication from the